To assess the safety and the efficacy of glycine in patients with acute ischemic stroke in the carotid artery territory.
- Glycine Drug
Intervention Desc: NMDA receptor co-agonist, also interacts with glycine receptors and GABA receptors. Believed to correct imbalances between excitatory and inhibitory neurotransmitter systems.
Randomized, double-blind, placebo-controlled trial of 200 patients.
Patients were randomized to receive placebo or 1 of 3 doses of glycine (0.5 g/day, 1.06/day, 2.0 g/day). Patients were assessed at the end of treatment (day 6) and at 30 days.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Safety, neurological outcome according to Orgogozo Stroke Scale (OSS) and Scandinavian Stroke scale (SSS), functional outcome according to Barthel index, mortality at day 30.|
|Secondary||Enzyme-linked immunosorbent assay (ELISA) of levels of blood serum autoantibodies to NMDA-binding proteins, detection of excitatory (glutamate, aspartate) and inhibitory (glycine, GABA) amino acid concentrations and lipid peroxidation products (TBARS) in CSF.|